153655-94-8

Basic information

• Product Name: tert-butyl-4-(3,4-dichlorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl-4-(3,4-dichlorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• CAS NO: 153655-94-8
• Molecular Weight: 328.238
• Mol File: 153655-94-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl-4-(3,4-dichlorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl-4-(3,4-dichlorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(153655-94-8)
• EPA Substance Registry System: tert-butyl-4-(3,4-dichlorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(153655-94-8)

Safety Data

• Hazardous Substances Data: 153655-94-8(Hazardous Substances Data)

Upstream product

• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 18282-59-2 4-bromo-1,2-dichlorobenzene 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 151169-75-4 3,4-dichlophenylboronic acid 

Downstream Products

• 1013097-76-1 1,1-dimethylethyl 4-(3,4-dichlorophenyl)-6-[2-(ethyloxy)-2-oxoethyl]-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 153655-92-6 4-(3,4-dichlorophenyl)-1,2,3,6-tetrahydropyridine 
• 153655-93-7 tert-butyl-4-(3,4-dichlorophenyl)piperidine-1-carboxylate 
• 99329-54-1 4-(3,4-dichlorophenyl)piperidine 
• 1394388-59-0 2-(2-(4-(3,4-dichlorophenyl)piperidin-1-yl)ethyl)isoindoline-1,3-dione 
• 1394388-61-4 2-(4-(3,4-dichlorophenyl)piperidin-1-yl)ethanamine 
• 1394387-95-1 2-(4-(3,4-dichlorophenyl)piperidin-1-yl)-N-((3-isopropylisoxazol-5-yl)methyl)ethanamine 
• 1574730-87-2 2-(2-(4-(3,4-dichlorophenyl)-5,6-dihydropyridin-1(2H)-yl)ethyl)isoindoline-1,3-dione 
• 1394388-63-6 2-(4-(3,4-dichlorophenyl)-5,6-dihydropyridin-1(2H)-yl)ethanamine 
• 1394387-90-6 2-(4-(3,4-dichlorophenyl)-5,6-dihydropyridin-1(2H)-yl)-N-((3-isopropylisoxazol-5yl)methyl)ethanamine 

Relevant articles and documents

Synthesis and biological evaluation of 1-(isoxazol-5-ylmethylaminoethyl)-4- phenyl tetrahydropyridine and piperidine derivatives as potent T-type calcium channel blockers with antinociceptive effect in a neuropathic pain model

New tetrahydropyridinyl and piperidinyl ethylamine derivatives were designed with hypothetical mapping on pharmacophore model generated from ligand-based virtual screening. The designed compounds were synthesized, and their inhibitory activities on T-type calcium channel were assayed using FDSS and patch-clamp assay. Among them, compounds 7b and 10b showed potent T-type calcium current blocking activity against Cav3.1 (α 1G) and Cav3.2 (α1H) channel simultaneously. With hERG and pharmacokinetics studies, compounds 7b and 10b were evaluated for the antinociceptive effect on rat model of neuropathic pain. They were significantly effective in decreasing the pain responses to mechanical and cold allodynia induced by spinal nerve ligation. These results suggest that modulation of α1G and α1H subtype T-type calcium channels may provide a promising approach for the treatment of neuropathic pain.

AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE

The present invention relates to novel compounds of formula (I)′, pharmaceutically acceptable salts, prodrugs or solvates thereof: wherein R1 is hydrogen or C1-4alkyl; R2 is a group A, K or W wherein A is (II) K is an α or β naphthyl group, optionally substituted by 1 or 2 groups R18, each of them being the same or different; and W is (III) and wherein G is a 5,6-membered monocyclic heteroaryl, or a 8- to 11-membered heteroaryl bicyclic group; such G may be substituted by (R15)p, which can be the same or different; p is an integer from 0 to 5; R3 is selected in the group consisting of: hydrogen, fluorine, and C1-4alkyl; or corresponds to a group X or X1; R4 is selected in the group consisting of: hydrogen, fluorine, and C1-4alkyl; or corresponds to a group X or X1; R5 is hydrogen or C1-4alkyl; R7 is hydrogen or C1-4alkyl; or is a group X, X1, X2 or X3; wherein X is (IV) X1 is (V) X2 is (VI) and X3 is (VII) R6 is hydrogen or C1-4alkyl; or is a group X or X1; R9 is C1-4alkyl; R10 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R8 is a 5-6 membered heterocycle group, which may be substituted by one or two substituents selected from a group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; R11 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4aIkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R12 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4aIkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R13 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R14 is selected from a group consisting of: hydrogen, halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4aIkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R15 is selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R8; R16 is hydrogen, C1-4alkyl, C3-6cycloalkyl or C3-6cycloalkylC1-3alkyl; R17 is hydrogen or C1-4alkyl; R18 is selected from a group consisting of: halog